Myriad Genetics, Inc. (MYGN)
| Previous Close | 15.25 |
| Open | 15.05 |
| Bid | 15.01 x 100 |
| Ask | 15.10 x 100 |
| Day's Range | 14.91 - 15.36 |
| 52 Week Range | 14.91 - 29.30 |
| Volume | |
| Avg. Volume | 760,462 |
| Market Cap | 1.373B |
| Beta (5Y Monthly) | 1.94 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.28 |
| Earnings Date | Nov 07, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 24.08 |
ZacksMYGN Stock Might Gain From SneakPeek Availability in Retail Stores
Myriad Genetics announces the availability of SneakPeek - the first at-home early fetal sex test in Walmart, Walgreens and CVS stores nationwide.
GlobeNewswireMyriad Genetics Expands Access to At-Home Early Fetal Sex DNA Test with Retail Launch
SneakPeek®, the first at-home early fetal sex test for use at six weeks, is now available at over 8,800 retail locations nationwideSALT LAKE CITY, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, continues to empower parents with increased access to prenatal testing. SneakPeek, the #1 OBGYN-recommended gender test with over 99% accuracy,[1] is now available over the counter in more than 8,800 retail locations nationwide.
Simply Wall St.Myriad Genetics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
Myriad Genetics ( NASDAQ:MYGN ) Third Quarter 2024 Results Key Financial Results Revenue: US$213.3m (up 11% from 3Q...
